Arrowhead Research | ARWR - Current Assets


Arrowhead Research reported $1.84B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Anika Therapeutics USD 93.56M 9.8M Mar/2026
Arrowhead Research USD 1.84B 665.36M Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Ligand Pharmaceuticals USD 865.42M 33.14M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Moderna USD 5.77B 774M Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Novartis USD 26.61B 3.85B Mar/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
TG Therapeutics USD 1.09B 456.2M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026
Xencor USD 482.85M 116.97M Mar/2026